Company: INSP
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001609550-25-000020
Chunk: 20

Company: Inspire Medical Systems, Inc.
Filing Date: 2025-05-05
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
 and fair value, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position:

10

Table of ContentsInspire Medical Systems, Inc. Notes to Consolidated Financial Statements (unaudited) (Table amounts in thousands, except share and per share amounts)

March 31, 2025Less than 12 Months12 Months or GreaterTotalFair ValueUnrealized LossFair ValueUnrealized LossFair ValueUnrealized LossCorporate debt securities$10,593 $(20)$— $— $10,593 $(20)U.S. Treasury debt securities69,029 (99)— — 69,029 (99)Total$79,622 $(119)$— $— $79,622 $(119)December 31, 2024Less than 12 Months12 Months or GreaterTotalFair ValueUnrealized LossFair ValueUnrealized LossFair ValueUnrealized LossCorporate debt securities$11,728 $(56)$— $— $11,728 $(56)U.S. Treasury debt securities69,402 (220)— — 69,402 (220)Total$81,130 $(276)$— $— $81,130 $(276)Investments are classified as available-for-sale and are reported at their estimated fair market values which are based on quoted, active or inactive market prices when available. Any unrealized gains and losses due to interest rate fluctuations and other external factors are reported as a separate component of accumulated other comprehensive income (loss) within stockholders' equity. We had $0.4 million of unrecognized gain in our accumulated other comprehensive income balance at both March 31, 2025 and December 31, 2024. Any realized gains and losses are calculated on the specific identification method and reported net in other (income) expense, net in the consolidated statements of operations and comprehensive income (loss). We recognized $0 of gross realized gains and losses from the sale or maturity of available-for-sale investments during each of the three months ended March 31, 2025 and 2024, respectively.As of March 31, 2025 and December 31, 2024, we had no investments with a contractual maturity of greater than two years. Currently, we do not intend to sell the investments, and it is not more likely than not that we will be required to sell the investments before recovery of their amortized